Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:OCS NASDAQ:OTLK NASDAQ:SPRY NASDAQ:ZVRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeOCSOculis$13.80-2.3%$20.24$10.52▼$34.47$818.74M0.44593,418 shs378,625 shsOTLKOncobiologics$1.42-2.1%$0.83$0.16▼$3.39$215.45M0.7715.94 million shs7.33 million shsSPRYARS Pharmaceuticals$8.33-2.7%$8.72$6.66▼$18.63$850.04M0.951.82 million shs1.12 million shsZVRAZevra Therapeutics$13.97-0.1%$11.76$7.16▼$14.58$826.43M0.851.75 million shs1.00 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceOCSOculis-2.27%+5.42%+23.10%-47.73%-27.20%OTLKOncobiologics-2.07%-15.98%+82.82%+566.67%-21.55%SPRYARS Pharmaceuticals-2.69%-2.69%-2.69%+2.21%-49.47%ZVRAZevra Therapeutics-0.07%-0.29%+31.67%+44.32%+42.77%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeOCSOculis$13.80-2.3%$20.24$10.52▼$34.47$818.74M0.44593,418 shs378,625 shsOTLKOncobiologics$1.42-2.1%$0.83$0.16▼$3.39$215.45M0.7715.94 million shs7.33 million shsSPRYARS Pharmaceuticals$8.33-2.7%$8.72$6.66▼$18.63$850.04M0.951.82 million shs1.12 million shsZVRAZevra Therapeutics$13.97-0.1%$11.76$7.16▼$14.58$826.43M0.851.75 million shs1.00 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceOCSOculis-2.27%+5.42%+23.10%-47.73%-27.20%OTLKOncobiologics-2.07%-15.98%+82.82%+566.67%-21.55%SPRYARS Pharmaceuticals-2.69%-2.69%-2.69%+2.21%-49.47%ZVRAZevra Therapeutics-0.07%-0.29%+31.67%+44.32%+42.77%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceOCSOculis 2.80Moderate Buy$38.33177.78% UpsideOTLKOncobiologics 2.00Hold$6.50357.75% UpsideSPRYARS Pharmaceuticals 2.50Moderate Buy$28.20238.54% UpsideZVRAZevra Therapeutics 2.82Moderate Buy$29.29109.63% UpsideCurrent Analyst Ratings BreakdownLatest OTLK, SPRY, ZVRA, and OCS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2026SPRYARS Pharmaceuticals Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$25.00 ➝ $24.006/24/2026OTLKOncobiologics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/24/2026ZVRAZevra Therapeutics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/23/2026ZVRAZevra Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$26.006/11/2026OCSOculis HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/11/2026OTLKOncobiologics Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$6.00 ➝ $10.006/10/2026ZVRAZevra Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$25.00 ➝ $29.006/10/2026ZVRAZevra Therapeutics Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$25.00 ➝ $35.006/9/2026ZVRAZevra Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$24.00 ➝ $29.006/9/2026ZVRAZevra Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/9/2026ZVRAZevra Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform(Data available from 7/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookOCSOculis$1.45M551.81N/AN/A$4.08 per share3.38OTLKOncobiologics$1.35M156.29N/AN/A($0.60) per share-2.37SPRYARS Pharmaceuticals$84.28M9.81N/AN/A$1.16 per share7.18ZVRAZevra Therapeutics$106.47M7.76$0.95 per share14.78$2.75 per share5.08Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateOCSOculis-$119.44M-$2.13N/AN/AN/A-8,460.67%-56.78%-45.62%8/6/2026 (Estimated)OTLKOncobiologics-$62.42M-$1.17N/AN/AN/AN/AN/A-291.28%8/13/2026 (Estimated)SPRYARS Pharmaceuticals-$171.30M-$2.01N/AN/AN/A-200.00%-153.61%-60.85%8/12/2026 (Estimated)ZVRAZevra Therapeutics$83.23M$1.9911.0114.71N/A101.58%51.49%28.86%8/11/2026 (Estimated)Latest OTLK, SPRY, ZVRA, and OCS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q2 2026OTLKOncobiologics-$0.12-$0.16-$0.04-$0.05$4.39 million$0.13 million5/15/2026Q1 2026SPRYARS Pharmaceuticals-$0.53-$0.61-$0.08-$0.61$22.20 million$22.68 million5/8/2026Q1 2026OCSOculis-$0.49-$0.63-$0.14-$0.61$0.25 million$0.26 million5/6/2026Q1 2026ZVRAZevra Therapeutics$0.06$0.18+$0.12$0.60$31.96 million$36.22 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthOCSOculisN/AN/AN/AN/AN/AOTLKOncobiologicsN/AN/AN/AN/AN/ASPRYARS PharmaceuticalsN/AN/AN/AN/AN/AZVRAZevra TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioOCSOculis0.015.185.18OTLKOncobiologicsN/A0.540.45SPRYARS Pharmaceuticals2.794.944.77ZVRAZevra TherapeuticsN/A4.894.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipOCSOculis22.30%OTLKOncobiologics11.20%SPRYARS Pharmaceuticals68.16%ZVRAZevra Therapeutics35.03%Insider OwnershipCompanyInsider OwnershipOCSOculisN/AOTLKOncobiologics1.80%SPRYARS Pharmaceuticals33.80%ZVRAZevra Therapeutics2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableOCSOculis257.98 millionN/ANot OptionableOTLKOncobiologics20148.59 million145.91 millionOptionableSPRYARS Pharmaceuticals9099.30 million65.74 millionOptionableZVRAZevra Therapeutics2059.12 million57.70 millionOptionableOTLK, SPRY, ZVRA, and OCS HeadlinesRecent News About These CompaniesZevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJune 30, 2026 | americanbankingnews.comZevra Therapeutics Announces Publication of Positive MIPLYFFA® Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC)June 23, 2026 | globenewswire.comZevra Therapeutics: Zevra's Chief Medical Officer to Step Down for Personal Reasons as Part of Planned TransitionJune 11, 2026 | finanznachrichten.deZevra’s Chief Medical Officer to Step Down for Personal Reasons as Part of Planned TransitionJune 11, 2026 | markets.businessinsider.comZevra's Chief Medical Officer to Step Down for Personal Reasons as Part of Planned TransitionJune 11, 2026 | globenewswire.comIs Zevra Therapeutics (ZVRA) Using MIPLYFFA Patent Extensions To Deepen Its Rare-Disease Moat?June 9, 2026 | finance.yahoo.comZVRA Stock Hits Its Highest Levels In Nearly 5 Years – What’s Driving This Sharp Rally Today?June 9, 2026 | finance.yahoo.comZevra Therapeutics extends MIPLYFFA exclusivity to 2041June 8, 2026 | finance.yahoo.comZVRA stock ‘way undervalued’? Analyst sees 117% upside after patent extends exclusivity till 2041 for sole approved drugJune 8, 2026 | msn.comZevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFAJune 8, 2026 | globenewswire.comZevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 29, 2026 | globenewswire.comZevra Therapeutics' (NASDAQ:ZVRA) Earnings Aren't As Good As They AppearMay 13, 2026 | finance.yahoo.comZevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor ConferenceMay 12, 2026 | globenewswire.comAnalysts Are Bullish on Top Healthcare Stocks: Zevra Therapeutics (ZVRA), Medicus Pharma Ltd (MDCX)May 11, 2026 | theglobeandmail.comZevra Therapeutics Earnings Call Highlights Growth PivotMay 10, 2026 | tipranks.comZevra Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen NextMay 9, 2026 | finance.yahoo.comZevra Therapeutics: Q1 Earnings SnapshotMay 7, 2026 | chron.comZevra (ZVRA) Q1 2026 Earnings Call TranscriptMay 7, 2026 | fool.comIs It Too Late To Consider Zevra Therapeutics (ZVRA) After The Recent Share Price Surge?May 7, 2026 | finance.yahoo.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Q1 2026 Earnings Call TranscriptMay 7, 2026 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOTLK, SPRY, ZVRA, and OCS Company DescriptionsOculis NASDAQ:OCS$13.80 -0.32 (-2.27%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$14.14 +0.34 (+2.45%) As of 07/6/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.Oncobiologics NASDAQ:OTLK$1.42 -0.03 (-2.07%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$1.41 -0.01 (-0.92%) As of 07/6/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.ARS Pharmaceuticals NASDAQ:SPRY$8.33 -0.23 (-2.69%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$8.40 +0.07 (+0.90%) As of 07/6/2026 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.Zevra Therapeutics NASDAQ:ZVRA$13.97 -0.01 (-0.07%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$14.10 +0.13 (+0.93%) As of 07/6/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Flash Crash or Cash? The AI Hardware Reset Investors Can’t Ignore KBR Insiders Are Buying While the Market Misreads Its Spinoff Doug Casey Calls AI a Super Bubble, Bets on Energy, Gold Miners and Grains Contrarian Alert: 5 Downgraded Stocks That May Reward Long-Term Investors This Edge AI Stock Just Got a Huge Vote of Confidence From Wall Street AI Is Selling Off, But These 5 Stocks Could Benefit Next MarketBeat Week in Review – 06/29 - 07/03 Analysts Just Raised Price Targets On These 3 Semiconductor Equipment Stocks Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
